» Articles » PMID: 23877587

Nephrology in China

Overview
Journal Nat Rev Nephrol
Specialty Nephrology
Date 2013 Jul 24
PMID 23877587
Citations 142
Authors
Affiliations
Soon will be listed here.
Abstract

China has a large population and a high prevalence of chronic kidney disease (CKD). The increasing incidence of obesity and type 2 diabetes mellitus, coupled with an ageing population, will exacerbate the burden of CKD unless effective control and prevention strategies are implemented. The unmet challenges of managing the growing number of patients with end-stage renal disease (ESRD) in China are reflected by the lower rate of patients receiving dialysis relative to many Western countries, owing to a lack of financial and clinical resources, and inequalities in access to health care across regions and populations. The feasibility of expanding peritoneal dialysis is being examined, and ongoing health-care reforms provide an invaluable opportunity to improve the status and quality of dialysis for patients with ESRD in China. The Chinese Society of Nephrology (CSN) advocates for efforts focused on preventing CKD coupled with early detection, treatment, and adequate follow-up to reduce mortality and the long-term burden of CKD. In addition, rapid advances in nephrology research, from basic science to clinical epidemiology, as well as broad communication and collaboration between the CSN and other international nephrology societies, will promote the development of nephrology in China.

Citing Articles

Care for end-stage kidney disease in China: progress, challenges, and recommendations.

Chen T, Sun X, Tsuei S, Yang R, Yip W, Fu H Lancet Reg Health West Pac. 2025; 54():101268.

PMID: 39811189 PMC: 11731773. DOI: 10.1016/j.lanwpc.2024.101268.


Yishen paidu pills attenuates 5/6 nephrectomy induced kidney disease via inhibiting the PI3K/AKT/mTOR signaling pathway.

Liu S, Cao Y, Yuan Q, Xie Y, Zhu Y, Yao L Front Pharmacol. 2024; 15:1510098.

PMID: 39669205 PMC: 11634598. DOI: 10.3389/fphar.2024.1510098.


Hierarchical Medical: What are the Factors Driving ESKD Patients to Choose Community Hemodialysis Centers in China? A Labelled Discrete Choice Experiment.

Xiong J, Zhang H, Ma H Patient Prefer Adherence. 2024; 18:2441-2454.

PMID: 39660223 PMC: 11629663. DOI: 10.2147/PPA.S484608.


1.25(OH)2D3 decreases PCNA and mTOR expression and alleviates renal injury in Thy-1 nephritis rat model.

Li J, Jin L, Ma H, Suo J, Yang R, Yang X PLoS One. 2024; 19(12):e0311000.

PMID: 39636964 PMC: 11620346. DOI: 10.1371/journal.pone.0311000.


Identification of Spatial Specific Lipid Metabolic Signatures in Long-Standing Diabetic Kidney Disease.

Zhang Y, Piao H, Chen D Metabolites. 2024; 14(11).

PMID: 39590877 PMC: 11596753. DOI: 10.3390/metabo14110641.


References
1.
Appel G, Contreras G, Dooley M, Ginzler E, Isenberg D, Jayne D . Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20(5):1103-12. PMC: 2678035. DOI: 10.1681/ASN.2008101028. View

2.
Chi-Man Yip W, Hsiao W, Chen W, Hu S, Ma J, Maynard A . Early appraisal of China's huge and complex health-care reforms. Lancet. 2012; 379(9818):833-42. DOI: 10.1016/S0140-6736(11)61880-1. View

3.
Che M, Yan Y, Zhang Y, Gu Y, Wang N, Chen N . [Analysis of drug-induced acute renal failure in Shanghai]. Zhonghua Yi Xue Za Zhi. 2009; 89(11):744-9. View

4.
Li J, Gao X, Bian Q, Guo Z, Mei X, Yu G . Comparative study of scientific publications in urology and nephrology journals originating from USA, China and Japan (2001-2010). PLoS One. 2012; 7(8):e42200. PMC: 3411650. DOI: 10.1371/journal.pone.0042200. View

5.
Gong Y, Zhang F, Ding F, Gu Y . Elderly patients with acute kidney injury (AKI): clinical features and risk factors for mortality. Arch Gerontol Geriatr. 2011; 54(2):e47-51. DOI: 10.1016/j.archger.2011.05.011. View